- Ticker
- ACAD
- Price
- 16.84
- Stock movement down
- -0.30 (-1.75%)
- Company name
- ACADIA Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsverdi
- 2.72B
- Ent verdi
- 2.69B
- Pris/omsetning
- 5.51
- Pris/bok
- 6.11
- Utbytte avkastning
- -
- Utbytte vekst
- -
- Vekst år
- -
- FCF-utbetaling
- -
- Etterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års avkastning
- -1.98%
- 3 års avkastning
- -15.41%
- 5 års avkastning
- -12.00%
- 10 års avkastning
- 25.85%
Sist oppdatert: 2022-08-25
UTBYTTE
ACAD betaler ikke utbytte
VERDSETTELSE
Verdsettelsesforhold
Loading...
Verdsettelsesforhold-data
| Etterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Verdsettelse (Salg/Bokført verdi)
Loading...
Verdsettelse (Salg/Bokført verdi) data
| Pris til omsetning | 5.51 |
| Pris til bok | 6.11 |
| EV i forhold til salg | 5.46 |
ØKONOMI
Per aksje
Loading...
Per aksje-data
| Gjeldende aksje antall | 161.43M |
| EPS (TTM) | -1.33 |
| FCF per aksje (TTM) | -0.88 |
Resultatregnskap
Loading...
Resultatregnskap-data
| Inntekter (TTM) | 493.06M |
| Bruttofortjeneste (TTM) | 475.66M |
| Driftsinntekter (TTM) | -216.68M |
| Netto inntekt (TTM) | -214.48M |
| EPS (TTM) | -1.33 |
| EPS (1 år fremover) | -0.74 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 96.47% |
| Driftsmargin (TTM) | -43.95% |
| Fortjenestemargin (TTM) | -43.50% |
Balanse
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Balanse-data
| Kontanter | 204.92M |
| Netto fordringer | 63.48M |
| Samlede omløpsmidler | 542.22M |
| Goodwill | 0.00 |
| Immaterielle eiendeler | 0.00 |
| Eiendom, anlegg og utstyr | 0.00 |
| Sum eiendeler | 624.25M |
| Leverandørgjeld | 10.77M |
| Kortsiktig/nåværende langsiktig gjeld | 64.42M |
| Sum kortsiktig gjeld | 119.60M |
| Sum gjeld | 179.45M |
| Aksjonærenes egenkapital | 444.80M |
| Netto varige driftsmidler | 444.80M |
Kontantstrøm
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Kontantstrøm-data
| Kontantstrøm fra drift (TTM) | -141.84M |
| Kapitalutgifter (TTM) | 47.00K |
| Fri kontantstrøm (TTM) | -141.89M |
| Utbetalt utbytte (TTM) | 0.00 |
Finansielle inntekter
Loading...
Opprett en gratis konto eller logg inn for å få tilgang til dette diagrammet
Finansielle inntekter-data
| Egenkapitalavkastning | -48.22% |
| Avkastning på eiendeler | -34.36% |
| Avkastning på investert kapital | -48.22% |
| Kontantavkastning på investert kapital | -31.90% |
AKSJEINFORMASJON
Aksjediagram
Loading...
Aksjekurs-data
| Åpning | 17.28 |
| Daglig høy | 17.34 |
| Daglig lav | 16.62 |
| Daglig volum | 871K |
| Tidenes høyeste | 57.00 |
| 1 år analytikerestimat | 22.06 |
| Beta | 0.72 |
| EPS (TTM) | -1.33 |
| Utbytte per aksje | - |
| Ex-div dato | - |
| Neste dato for resultatpresentasjon | 7 Nov 2022 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ACAD | S&P500 | |
| Nåværende prisfall fra toppnotering | -70.46% | -12.18% |
| Høyeste prisfall | -96.29% | -56.47% |
| Dato for høyeste fall | 12 Nov 2010 | 9 Mar 2009 |
| Gj.snittlig fall fra topp | -47.36% | -11.38% |
| Gj.snittlig tid til ny topp | 50 days | 12 days |
| Maks tid til ny topp | 1820 days | 1805 days |
SELSKAPSOPPLYSNINGER
Markedsverdi
2.72B
Markedsverdi kategori
Mid-cap
Beskrivelse
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
Ansatte
500
Nettsted
Investorrelasjoner
-
SEC-innsendelser
Adm. direktør
Stephen R. Davis
Land
USA
By
San Diego
Aksjetype
Common stock
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRESENTASJONER
ArrangementerPresentasjoner
Loading...
FORSTÅ VIRKSOMHETEN
Loading...
NYHETER OM SELSKAPET
Alle nyheterPressemeldinger
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
13. september 2022
SAN DIEGO, September 12, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) of tro...
12. september 2022
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
7. september 2022
SAN DIEGO, September 01, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at the following upcoming investor conferences:
1. september 2022
The mean of analysts' price targets for Acadia (ACAD) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...
30. august 2022
Acadia (ACAD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
26. august 2022
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) non-opioid painkiller. The company ...
9. august 2022
Acadia (ACAD) reports a narrower-than-expected loss for the second quarter of 2022 while revenues surpass estimates. Tightens guidance for Nuplazid.
9. august 2022
Acadia (ACAD) delivered earnings and revenue surprises of 16% and 2.82%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
8. august 2022
SAN DIEGO, August 08, 2022--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2022.
8. august 2022
Neste side